Portal hypertension didanosine

Liver Long-term didanosine therapy was associated with non-cirrhotic portal hypertension in three HIV-positive individuals with chronic hepatitis C, mild liver fibrosis, and... [Pg.587]

In a nested case-control study conducted by the Swiss HIV Cohort there was a strong association between prolonged exposure to didanosine and non-cirrhotic portal hypertension [107 ]. In 15 patients with non-cirrhotic portal hypertension and 75 controls matched for duration of HIV infection, absence of viral hepatitis, and duration of follow-up, cumulative exposure to antiretroviral drug therapy (OR per year = 1.3 95% Cl = 1.0,1.6), nucleoside reverse transcriptase inhibitors (OR = 1.3 95% Cl = 1.1, 1.7), didanosine (OR = 3.4 95% Cl = 1.5, 8.1), ritonavir (OR = 1.4 95% Cl = 1.0, 1.9), and nelfinavir (OR = 1.4 95% Cl = 1.0,1.9) were longer in the patients with portal hypertension. Exposure to non-nucleoside reverse transcriptase inhibitors and other protease inhibitors were not different. [Pg.587]

Liver A further case of non-cirrhotic portal hypertension has been reported with didanosine [152 ]. [Pg.416]

Chang HM, Tsai HC, Lee SS, Warm SR, Chen YS. Noncirrhotic portal hypertension associated with didanosine a case report and literature review. Jpn J Infect Dis 2012 65(l) 61-5. [Pg.437]

Big Chemical Encyclopedia